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Previous studies have suggested the involvement of N-Methyl,D-Aspartate (NMDA) pathway in the 
Pathophysiology of anxiety disorder. However the role f NMDA neurotransmission in the neurobiology of 
different classes of anxiety disorder remains unexplored. This study examined the effects of intraperitoneal 
administration of acute (3 mg/kg) and withdrawal from chronic administration of non-competitive NMDA 
receptor antagonist - ketamine (15 mg/kg daily for 21 days and withdrawn for 24 hours) on inhibitory 
avoidance duration (conditioned fear related behaviour) and escape latency (unconditioned fear related 
behaviour) using the elevated-T-maze (ETM) in mice (n = 10). The results showed that acute ketamine reduced 
while withdrawal from chronic ketamine administration increased inhibitory avoidance duration significantly 
(p < 0.05). Acute ketamine also increased escape latency, but withdrawal from chronic ketamine reduced 
escape latency significantly (p < 0.05). It was inferred that acute ketamine decreased conditioned and 
unconditioned fear related behaviours as a result of NMDA transmission downregulation, while withdrawal 
from chronic ketamine induced increase in conditioned and unconditioned related behaviours via NMDA 
transmission upregulation. Changes in NMDA transmission appear to be relevant in the neurobiology of 
generalized anxiety disorder and panic disorder related behaviours in the ETM, hence pharmacological 
modulation of NMDA transmission may contribute to improved treatment of generalised anxiety and panic 
disorders. 
© 2014 International Formulae Group. All rights reserved. 
 




Clinical anxiety disorder is 
heterogeneous, comprising generalised 
anxiety disorder, panic disorder, obsessive 
compulsive disorder, specific phobia, 
posttraumatic stress disorder and social 
anxiety disorder (APA 1994). Different 
animal models have been developed to study 
each of the anxiety disorders at the preclinical 
level (Graeff and Del-Ben, 2008, Johnson et 
al., 2012). Specifically, the elevated T-maze 
(ETM) was developed by Graeff et al. (1998) 
to assess two types of anxiety-related 
behavioural tasks (acquisition of inhibitory 
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avoidance and escape latency). The ETM 
consists of three elevated arms, one enclosed 
and two open. Inhibitory avoidance 
representing learned or conditioned fear is the 
time taken to leave the enclosed arm in three 
consecutive trials. Unconditioned fear is the 
time to escape from the open arm (Graeff et 
al., 1998).  Results of previous behavioural 
and pharmacological profile of the ETM 
support the view that inhibitory avoidance 
(conditioned fear)  in the elevated T-maze is 
related to generalized anxiety disorder, while 
one-way escape (unconditioned fear ) is  
associated with panic disorder (Graeff et al., 
2002).   
Several neurotransmitter systems 
including the NMDA transmission have been 
implicated in the neurobiology of anxiety 
disorders (Garakin et al., 2006; Amiel and 
Sanjay, 2007; Davis, 2011). However the 
exact role of NMDA transmission on different 
types of anxiety disorders has not been 
explored. Hence this study intends to 
investigate the role of NMDA transmission in 
two types of experimental anxiety 
(conditioned - passive avoidance and 
unconditioned - one way escape) using the 
elevated T-maze and pharmacological tools 
(ketamine – a non-competitive NMDA 
receptor antagonist). The result of this study is 
expected to suggest the possible role of 
NMDA transmission in conditioned and 
unconditioned fear related behaviours, thus 
contributing to the existing knowledge on the 
neurobiology and possible improved treatment 
outcome of anxiety disorder. 
 
MATERIALS AND METHODS 
Animals 
Adult albino mice (20–30 g), used for 
all investigations were bred and housed in a 
well ventilated room, maintained under a 
natural dark/light cycle, ambient temperature 
of 28 ± 2 °C and were allowed food and water 
ad libitum. Animals were kept in cubic plastic 
cages (25 cm X 16 cm X 12 cm), with a wire 
mesh top surface for maximal ventilation and 
illumination. In all, ten animals comprising 
equal number of males and females were used 
per group. The experimental protocols 
followed the internationally accepted 
principles for laboratory animal use and care 
(EEC directive of 1986; 86/609/EEC).  
 
Drugs 
Ketamine (Rotex Medica, Trittau, 
Germany) was used. The drug was dissolved 
in normal saline as the vehicle for 
intraperitoneal administration (i.p.). Drugs 
used were delivered to the animals 
intraperitoneally at volume of 10 mls/kg body 
weight. The drug dosages were chosen based 
on previous studies (Hyung-Wook et al., 
2009).  
 
Drug treatment protocol for assessment of 
inhibitory avoidance duration and escape 
latency 
The following treatment protocol was 
employed for this study. Animals were 
randomly divided into 4 groups of 10 animals 
each. Groups 1 and 2 were used for the acute 
drug treatment while groups 3 and 4 were 
subjected to chronic drug treatment as 
indicated below. 
Acute drug treatments: 
Group 1 saline (10 mls/kg, i.p.) 
Group 2. ketamine (3 mg/kg, i.p.) 
Chronic drug treatment 
Group 3. saline (10 mls/kg, i.p.) daily for 21 
days 
Group 4.  ketamine (15 mg/kg, i.p.) daily for 
21 days. 
 
The elevated T-maze for assessment of 
inhibitory avoidance duration and escape 
latency 
The T-maze was made of wood, and 
had three arms of equal dimensions (30 X 5 
cm). One arm, enclosed by walls 20 cm high, 
was perpendicular to two opposed open arms. 
To avoid falls, the open arms were surrounded 
by a 0.5 cm high wooden rim. The whole 
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apparatus was elevated 50 cm above the floor 
(Graeff et al., 1993).  
 
Assessment of inhibitory avoidance 
duration and escape latency using the 
elevated T-maze   
Assessment of the inhibitory avoidance 
and escape latency was conducted according 
to the methodology of Graeff and co-workers 
(1993). On the second and third days after 
their arrival in the laboratory, the animals 
were gently handled for 10 minutes. On the 
fourth day, all animals were exposed to one of 
the open arms of the elevated T-maze (ETM) 
for 30 min. Wood barriers mounted on the 
border of the maze central area and the arm’s 
proximal end isolated the open arm of the 
ETM. Exposure of the mice to the open arms 
of the ETM being a novelty to the mice, is 
expected to induce exploratory behaviour 
including increase in their locomotor activity 
(Tchernikovski and Golani, 1995). It has been 
reported that this exploratory activity 
interferes with escape latency in naive animal 
(Graeff et al., 1993). The pre-test exposure to 
open arms of the ETM was done 24 hours 
prior to conduct of the acute and chronic 
studies.  Pre-test exposure (training) of the 
animals to the open arm of the elevated T-
maze for 10 minutes, 24 hours before the test 
leads to habituation of exploration, thus 
eliminating the influence of novelty on the 
escape latency. Withdrawal from the open arm 
following pre-test exposure was suggested as 
a better index of escape latency (Graeff et al., 
1998).  
 The elevated T-maze test was 
performed 24 hrs after the pre-test exposure. 
Five minutes after acute drug or vehicle 
treatment and 24 hrs after the last dose of 
chronic drug or vehicle treatment, animals 
were placed at the distal end of the enclosed 
arm facing the intersection of the arms. The 
mouse was left alone until it leaves the 
enclosed arm with its four paws. The same 
procedure was repeated twice at 30-s 
intervals. The time taken for the animal to 
leave the enclosed arm at each trial was 
recorded as the inhibitory avoidance duration 
(IAD). One minute after the conclusion of the 
inhibitory avoidance session, the mouse was 
placed at the end of the open arm and the time 
taken to leave the arm with the four paws was 
recorded (escape latency - EL).  
 
Statistical analysis 
The results were presented as means ± 
standard error of means. The significance of 
changes in inhibitory avoidance duration and 
escape latency between control and 
experimental groups were analyzed using one-
way analysis of variance (ANOVA), followed 
by Student-Newman-Keuls (SNK) test. 
 
RESULTS 
Effect of acute and chronic treatments with 
Saline, and Ketamine on inhibitory 
avoidance duration and escape latency on 
elevated T maze in mice 
One way ANOVA revealed significant 
difference (F3,36 = 163.18, p < 0.05 ), (F3,36 = 
110.96, p < 0.05) in the inhibitory avoidance 
duration across treatment groups at the second 
and third exposures respectively. Post hoc 
analysis revealed that while acute ketamine 
significantly decreased inhibitory avoidance 
duration relative to acute saline group (p < 
0.05), chronic ketamine significantly 
increased inhibitory avoidance duration 
relative to the chronic saline group (p < 0.05) 
at the second and third exposures. 
There was significant difference in 
escape latency (F3,36 = 17.35, p < 0.05) across 
all treatments groups. While acute ketamine 
significantly increased escape latency relative 
to acute saline group, chronic ketamine 
significantly reduced escape latency relative 
to chronic saline group (p < 0.05). 
     
 
 





Figure 1: Effect of acute and chronic treatments with Saline (SAL), and Ketamine (KET) on 
inhibitory avoidance duration on elevated T maze at first exposure (IAD1) in mice. Each bar represents 




Figure 2: Effect of acute and chronic treatments with Saline (SAL), and Ketamine (KET) on 
inhibitory avoidance duration on elevated T maze at second exposure (IAD2) in mice. Each bar 
represents mean ±  SEM. (n = 10). * p < 0.05 relative to acute saline, # p < 0.05 relative to chronic saline. 
 




Figure 3: Effect of acute and chronic treatments with Saline (SAL), and Ketamine (KET) on 
inhibitory avoidance duration on elevated T maze at second exposure (IAD2) in mice. Each bar 
represents mean ±  SEM. (n = 10). * p < 0.05 relative to acute saline, # p < 0.05 relative to chronic saline. 
 
Figure 4: Effect of acute and chronic treatments with Saline (SAL), and Ketamine (KET) on escape 
latency on elevated T maze in mice. Each bar represents mean ± SEM. (n = 10). * p < 0.05 relative to acute saline,   
# p < 0.05 relative to chronic saline. 
 




The elevated T maze (ETM) - derived 
from the widely used elevated X- or plus-
maze (Handley and Mithani, 1984 ; Pellow et 
al., 1985), was introduced as an animal model 
of anxiety with the aim of simultaneous study 
of conditioned (related to generalized anxiety 
disorder) and unconditioned types of fear 
(related to panic disorder). The inhibitory 
avoidance duration (IAD) was proposed to 
represent learned (conditioned) fear (Graeff et 
al., 1998) while the escape latency (EL) from 
the open arms into the enclosed arms is a 
measure of unconditioned fear (Teixeira et al., 
2000).  
It was observed that acute ketamine – a 
non-competitive N-methyl,D-Aspartate 
(NMDA) receptor antagonist significantly 
suppressed IAD, but increased EL relative to 
the saline treated group. These results suggest 
that acute inhibition of NMDA transmission 
suppressed both conditioned and 
unconditioned types of fear-related behaviour 
on the ETM. Several lines of evidence 
indicate that NMDA receptor ligands 
modulate anxiety in rodents (Chojnacka-
Wójcik et al., 2001; Wiley et al., 1995). 
Furthermore the anxiolytic potential of acute 
treatment with NMDA receptor blockers has 
been widely reported (Blanchard et al., 1992; 
Plaznik et al., 1994). In general, antagonism 
of the NMDA receptor has been linked with 
anxiolytic behaviour in rodents (Corbett and 
Dunn, 1991).  Furthermore, genetic 
inactivation of the NMDA receptor NR2A 
subunit has been reported with anxiolytic 
effects in mice (Boyce-Rustay and Holmes, 
2006). Hence the inhibition of learned and 
unconditioned types of fear by acute ketamine 
as reported in this study can be attributed to its 
NMDA receptor blocking effect (Plaznik et 
al., 1994). This is supported by reported 
changes in NMDA transmission following 
chronic treatments with some anxiolytic drugs 
(Popik et al., 2000). 
Contrary to its acute effect, withdrawal 
from chronic ketamine increased conditioned 
and unconditioned fear related behaviours 
significantly when compared with saline 
treated groups. Chronic treatment with 
ketamine has been reported to up-regulate 
NMDA receptor and increased transmission in 
the NMDA pathway may occur during the 
early period of withdrawal from chronic 
treatment with the NMDA receptor antagonist 
(Follessa and Ticku, 1996; Economou and 
Angelatou, 1999; Nagy, 2008). The increase 
in conditioned and unconditioned type of fear 
following withdrawal from chronic ketamine 
treatment can be explained by the increased 
excitatory transmission in the NMDA 
pathway. Exposure to fearful stimuli has been 
reported to be accompanied with increased 
NMDA receptor expression and mRNA levels 
in the rat ventral tegmental area and 
hippocampus (Bartanusz et al., 1995; 
Fitzgerald et al., 1996). Similarly, positive 
modulators of NMDA transmission have been 
reported with anxiogenic properties (Swanson 
et al., 2005). 
 
Conclusion  
The results of this study clearly 
demonstrated that NMDA transmission is 
relevant in the neurobiology of conditioned 
and unconditioned fear in mice.   It can be 
inferred that down-regulation of NMDA 
transmission may be a relevant pathway in the 
various treatment modalities of generalized 
anxiety and panic disorder, hence may play an 
important role in the therapeutic mechanism 
of anxiolytics. Pharmacological modulation of 
NMDA transmission may be explored for 
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